Notch�ź�ͨ·��ϸ��Ƽ��о��չ

[1]

PATHAK S. Organ and tissue-specific stem cells and carcinogenesis. Int Institute Anticancer Res, 2002, 22(3):1353-1356. [2] NDUOM E K, HADJIPANAYIS C G, VAN MEIR E G. Glioblastoma cancer stem-like cells:Implications for pathogenesis and treatment . Cancer J, 2012, 18(1):100-106. [3] DITTMER, JURGEN R, ACHIM. Cancer stem cells in breast cancer. Histology and Histopathology, 2013, 28(7):827-838. [4] HASSAN K A, WANG L, KORKAYA H, et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res, 2013, 19(8):1972-1980. [5] WU J N, JI Z Y, LIU H L, et al. Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway . Toxicol Lett, 2013, 220(1):61-69. [6] WANG Z W, SHADAN A, SANJEEV, et al. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. J Cellular Physiol, 2009, 228(3):556-562. [7] WANG Z W, LI Y W, SANJEEY B. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kB signaling pathways. J Cell Biochem, 2011, 112(1):78-88. [8] INGRID E, LUCIO M. Notch inhibitors for cancer treatment. Pharmacol Ther, 2013, 139(2):95-110. [9] CASPER G, MARK E. F. Therapeutic approaches to modulating Notch signaling:Current challenges and future prospects. Seminars in Cell & Developmental Biology, 2012, 23(4):465-472. SELL S. Cancer and stem cell signaling:A guide to preventive and therapeutic strategies for cancer stem ceils. Stem Cell Bev, 2007, 3(1):1-6. NEFEDOVA Y, SULLIVAN D M, BOLICK S C, et al. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood, 2008, 111(4):2220-2229. CHU L, HUANG Q, ZHANG Q B, et al. Effect of ABCG2 on drug resistance gene of brain tumor stem cells. Chin Pharm J(�й�ҩѧ��־), 2009, 44(10):754-758. CHIU H W, HO Y S, WANG Y J. Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of surviving. J Mol Med, 2011, 89(9):927-941. AL-HAJJ M, WICHE M S, BENITO-HERNANDEZ A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 2003, 100(7):3983-3988. STEFANIE L M, GREGORY A W, DANIELA M D, et al. ��Take it up a NOTCH:�� Novel strategies for cancer therapy. Cell Cycle, 2012, 12(2):191-192. WANG Z, LI Y, BANERJEE S, et al. Emerging role of Notch in stem cells and cancer. Cancer Lett, 2009, 279(1):8-12. PATRAWALA L, CALHOUN T, SCHNEIDER R, et al. Highly purified CD44⁺ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene, 2006, 25(10):1696-1670. MUHAMMAD A, CRAIG D, PEACOCK, et al. Cancer stem cells in lung cancer:Evidence and controversies. Respirology, 2013, 18(5):757-764. KIM C F, JACKSON E L, WOOLFENDEN A E, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell, 2005, 121(6):823-825. PASSEGUE E, JAMIESON C H, AILLES L E, et al. Normal and leukemic hematopoiesis are leukemias a stem cell disorder or a reacquisition of stem cell characteristics. Proc Natl Acad Sci USA, 2003, 100(1):11842-11849. CHIANG M Y, SHESTOVA O, XU L, et al. Divergent effects of supraphysiologic Notch signals on leukemia stem cells and hematopoietic stem cells. Blood, 2013, 122(2):155-156. SHACHAF C M, KOPELMAN A M, ARVANITIS C, et al. MYC Inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature, 2004, 431(7012):1112-1117. TETSUHIRO C, ZHENG Y W, KAORU K, et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology, 2007, 133(3):937-950. ZHU Z, HAO X, YAN M, et al. Cancer stem/progenitor cells are highly enriched in CD133⁺CD44⁺population in hepatocellular carcinoma. Int J Cancer, 2010, 126(9):2067-2078. GAN J, CHEN C, HONG L, et al. RUNX3 Directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells. Exp Cell Res, 2010, 316(2):149-157. YAO Z X, MISHRA L. Cancer stem cell hepatocellular carcinoma. Cancer Biol, 2009, 8(18):1691-1698. WANG C, QI R, LI N, et al. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and upregulating p53-dependent DR₅ expression. Biol Chem, 2009, 284 (24):16183. WU X, CAI Z, ZHU Q G, et al. Targeting gene delivery to prostatic cancer with mAb-conjugated polyamidoamine dendrimers. Chin J Pharm(�й�ҩѧ��־), 2012, 47(6):418-422. GU G, YUAN J, WILLS M L, et al. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res, 2007, 67(5):4807-4815. NORMAN J M, ANNE C. Tumour stem cell hypothesis for the origins of prostate cancer. BJU Int, 2005, 96(9):1219-1223. JOSEP D D, SAMUEL J V L, VERONICA R B, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of Notch-and hedgehog-dependent tumor-initiating cells. Cancer Cell, 2012, 22(3):373-388. FILIPE L F, BRIAN S, BERMAN D M. Abstract B56:Notch signaling in prostate cancer progression. Cancer Res, 2012, 72(4):1931-1940. LI C W, DAVID G H, PIERO D, et al. Identification of pancreatic cancer stem cells. Cancer Res, 2007, 67(3):1030-1037. NADE�cDA L, JANINA D, BERUT�� K, et al. Association between Notch signaling pathway and cancer. Acta Med Lituanica, 2012, 19(4):427-437. MAZUR P K, EINWACHTER H, LEE M, et al. Notch2 is required for progression of pancreatic intraepithelial neo-plasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA, 2010, 107(30):13438-13443. ANTONIO P, KIMBERLY F, PAOLA R, et al. Targeting Notch to target cancer stem cells. Clin Cancer Res, 2010, 16(12):3141-3152. RAYMOND E M, MELANIE C, TIA N D, et al. Direct inhibition of the NOTCH transcription factor complex. Nature, 2009, 462(1038):182-188. ASTE-AM��ZAGA M, ZHANG N, LINEBERGER J E, et al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One, 2010, 5(2):9094. WU Y, CAINHON C, CHOY L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature, 2010, 464(7291):1052-1057. LI K, LI Y, WU W, et al. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of Notch3. J Biol Chem, 2008, 283(12):8046-8054. INGRID E, SPINOZ A, LUCIO M, et al. Notch inhibitor for cancer treatment. Pharmacol Ther, 2013, 139(2):95-110. HAYASHI I, TAKATORI S, URANO Y, et al. Neutralization of the gamma-secretase activity by monoclonal antibody against extracellular domain of nicastrin. Oncogene, 2012, 31(6):787-798. SCHMIDT M H, BICKER F, NIKOLIC I, et al. Epidermal growth factor-like domain 7 (EGFL7) modulates Notch signalling and affects neural stem cell renewal. Nat Cell Biol, 2009, 11(7):873-880. NICHOL D, SHAWBER C, FITCH M J, et al. Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7. Blood, 2009, 16(26):6133-6143. NEFEDOVA Y, SULLIVAN D M, BOLICK S C, et al. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood, 2008, 111(4):2220-2229. MENG R D, SHELTONC C, LI Y M, et al. Gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-l signaling pathway in colon cancer ceils resulting in enhanced chemosensitivity. Cancer Res, 2009, 69(2):573-582. WASAG B, NIDOSZYTKO M, PISKORZ A, et al. Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol, 2011, 39(8):859-865. JIALIANG W, TP W, JUSTIN D L, et al. Notch promotes radioresistance of Glioma stem cells. Stem Cell, 2010, 28(1):17-28. KE H, SHIMIZU F, WANG R, et al. Inhibition of Notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cell, 2010, 28(6):1019-1029. XU D, HU J, XU S, et al. Dll1/ Notch activation accelerates multiple myeloma disease development by promoting CD138t MM-cell proliferation. Leukemia, 2012, 26(12):1402-1414. NIKOLAKOPOULOSL A D K, GIANNOPOULOU E. Inhibition of Notch pathway in non-small cell lung cancer . Annals of Oncology, 2013, 24(1):i21-i22. HARRISON H, FARNIE G, HOWELL S J, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res, 2010, 70(2):709-718. COOK J J, WILDSMITH K R, GILBERTO D B, et al. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. Neurosci, 2010, 30(19):6743-6750. ANNE F S, MELISSA D L, GABRIELA D, et al. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res, 2013, 19(6):1512-1524. JOYCE O O, IRINA D, PETER B I, et al. Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Mol Cancer Res, 2011, 9(12):1746. NATALIE C, KRISTOPHER K F, TASHINGA E B, et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med, 2012, 209(3):437-444. FOULADI M, STEWART C F, OLSON J, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies:A pediatric brain tumor consortium study. Clin Oncol, 2011, 29(26):3529-3534. TAMMAM J, WARE C, EFFERSON C, et al. Down-regulation of the Notch pathway mediated by a ��-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol, 2009, 158(5):1183-1195. PANDYA K, MEEKE K, CLEMENTZ A G, et al. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Pharmacol, 2011, 105(8):796-806. JONATHAN R S, TIMOTHY Y, JILLWEBER, et al. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer, 2012, 48(7):997-1003. WEI P, MARLENA W, QIU M, et al. Evaluation of selective ��-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther, 2010, 9(6):1618-1628. ZHAO M, TANG S N, JUSTIN L M, et al. Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice. Cancer Lett, 2013, 337(2):210-217. KAWAHARA T, KAWAGUCHI-IHARA N, OKUHASHI Y, et al. Cyclopamine and quercetin suppress the growth of leukemia and lymphoma cells. Anticancer Res, 2009, 29(11):4629-4632. ANDREAS G, WILLIAM P S, KAREN B. Resveratrol in the management of human cancer: How strong is the clinical evidence?. Ann NY Acad Sci, 2013, 1290:12-20. YAN B, ZHOU Y Q, FENG S H, et al. ��-Elemene-attenuated tumor angiogenesis by targeting Notch-1 in gastric cancer stem-like cells. Evid Based Complement Alternat Med, 2013(2013):268480. WUA J N, JIA Z Y, LIUA H L, et al. Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway. Toxicol Lett, 2013, 220(1):61-69.